Off-Label Therapeutic Potential of Crisaborole.

Journal of Cutaneous Medicine and Surgery
Caitlyn MakinsParbeer S Grewal

Abstract

Crisaborole, a topical phosphodiesterase-4 inhibitor, was recently approved in 2016 for the treatment of mild to moderate atopic dermatitis in adults and children greater than 2 years of age. Since that time, several case reports and a small randomized controlled trial have been published regarding the off-label use of crisaborole for the treatment of other inflammatory dermatologic disorders. This paper reviews the current, albeit limited, evidence for off-label use of crisaborole for psoriasis, seborrheic dermatitis, vitiligo, and inflammatory linear verrucous epidermal nevus. Additional potential therapeutic uses for crisaborole are also postulated, based on its mechanism of action. Future studies are required to elucidate the full therapeutic potential of crisaborole; however, it is a welcome addition to the current nonsteroid topical treatments for inflammatory dermatologic disease.

References

May 1, 1996·Mycoses·R M RiciputoA Sapuppo
Jan 17, 2007·Journal of the American Academy of Dermatology·Electra NicolaidouAndreas D Katsambas
Apr 17, 2010·The Journal of Dermatological Treatment·Osman KöseZafer Kurumlu
Feb 14, 2014·Science Translational Medicine·Mehdi RashighiJohn E Harris
Dec 17, 2014·The Australasian Journal of Dermatology·Benjamin S Daniel, Richard Wittal
Dec 22, 2015·The British Journal of Dermatology·M WhittonK Ezzedine
Aug 22, 2017·Journal of the American Academy of Dermatology·Lawrence F EichenfieldEduardo Tschen
Oct 22, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·R BissonnetteD M Pariser
May 31, 2018·The Journal of Dermatological Treatment·Erica B LeeJashin J Wu
Aug 10, 2018·JAMA Dermatology·Allison B RobbinsMelanie R Bui
Apr 13, 2019·Dermatologic Therapy·Imran MajidSameena Batool

❮ Previous
Next ❯

Citations

Jun 3, 2020·Pharmaceutics·Adriana FantiniPatrizia Santi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.